Valencia-based computational drug discovery company applying QSAR modeling and machine learning to peptide pharmacokinetics and anti-cancer drug design.
MOLDRUG AI SYSTEMS is a Valencia-based private company specializing in computational drug discovery, applying machine learning, chemoinformatics, and quantitative structure-activity modeling to accelerate pharmaceutical research. Their core work involves building predictive models that link molecular structure to pharmacological behavior — specifically how drug candidates are absorbed, distributed, metabolized, and excreted. They have hosted MSCA Individual Fellows working on two distinct challenges: predicting the pharmacokinetics of therapeutic peptides, and identifying new anti-cancer compounds by computationally targeting G-quadruplex DNA structures through multi-target QSAR approaches. Their business model appears to be providing research infrastructure and scientific leadership to attract and host high-caliber individual researchers funded by EU fellowships.
Both PeptiMOL and G4-mtQSAR are built around QSAR-family methods — PeptiMOL applied QSPKR to peptide pharmacokinetics, while G4-mtQSAR extended multi-target QSAR to anti-cancer drug identification.
Drug discovery is the explicit application domain across both projects, using computational simulations and chemoinformatics tools to reduce reliance on wet-lab experimentation.
PeptiMOL (2020–2022) focused specifically on modeling the pharmacokinetic profiles of therapeutic peptides, a technically demanding area where peptide chemical space differs substantially from small molecules.
G4-mtQSAR (2021–2023) introduced machine learning and computational simulations targeting G-quadruplex DNA structures, representing a more data-driven direction compared to the earlier chemoinformatics-only work.
Their two-project trajectory shows a clear methodological shift: the earlier PeptiMOL project was grounded in classical chemoinformatics — QSPKR modeling, computational chemistry, pharmacokinetics — applied to the specialized challenge of therapeutic peptides. The later G4-mtQSAR project moved toward machine learning and multi-target computational approaches, with cancer as the disease focus and G-quadruplex DNA as a specific molecular target. In short, they moved from pharmacokinetics modeling toward AI-driven multi-target drug identification, with oncology emerging as a strategic application area.
They are moving from classical chemoinformatics toward machine learning-integrated, multi-target computational approaches in oncology — suggesting future projects will likely sit at the intersection of AI and precision cancer pharmacology.
MOLDRUG AI SYSTEMS has operated exclusively as a coordinator and host institution under the MSCA Individual Fellowships scheme, which by design does not involve consortia — a fellow joins the host, and the host guides the research. This means their "collaboration" record reflects zero formal consortium partners, not isolation: they attract individual researchers to work within their computational infrastructure. For potential partners, this signals an organization comfortable leading scientific direction but with limited experience navigating large multi-partner EU project management.
Their formal H2020 network consists solely of the MSCA fellows they hosted — no consortium partners and no cross-border institutional collaborations are recorded. As a Valencia-based entity operating under fellowship-only funding, their documented European reach is currently minimal.
MOLDRUG AI SYSTEMS occupies a specific niche: a private company — not a university or public research institute — that successfully competes for and hosts MSCA Individual Fellows, positioning itself as a credible research environment for top computational chemists. This is unusual; most MSCA-IF hosts are academic institutions, making MOLDRUG a rare private-sector bridge between academic-grade computational drug discovery and commercial application. For consortium builders, they bring focused AI/QSAR expertise without the overhead of a large academic partner, and their cancer and peptide work spans two growing pharmaceutical markets.
